Navigation Links
BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
Date:9/19/2007

.biocryst.com or by dialing 1-800-860- 2442 (U.S.) or 1-412-858-4600 (international). No passcode is needed for the call.

BioCryst is also currently conducting a Phase II clinical trial studying an intravenous formulation of peramivir in hospitalized patients. That trial is designed to compare the efficacy and safety of intravenous peramivir to orally administered oseltamivir in patients who require hospitalization due to acute influenza.

BioCryst is developing peramivir injection for the treatment of acute influenza, including infection caused by highly virulent, life-threatening strains of influenza. In January, 2006 BioCryst received FDA Fast Track designation for the development of peramivir injection for this indication.

BioCryst is advancing the clinical development of peramivir under terms of a contract from the U.S. Department of Health and Human Services (DHHS) which on January 3, 2007 awarded BioCryst a $102.6 million, four-year contract to develop peramivir for the treatment of seasonal and life-threatening influenza. Funding from the contract will support Phase II and Phase III product development activities including manufacturing of clinical lots, process validation, clinical studies and other product approval requirements needed for U.S. licensure. BioCryst has retained all of its development and commercialization rights to peramivir worldwide except for in Japan and Korea where BioCryst recently established strategic partnerships with Shionogi & Co. in Japan, and Green Cross in Korea.

About Peramivir

Peramivir is a member of the class of antiviral agents that inhibit influenza viral neuraminidase, an enzyme that is essential for the spread of influenza virus within the host. Peramivir is an inhibitor of influenza A and B neuraminidases and certain strains of influenza viruses that may be resistant to available neuraminidase inhibitors but are susceptible to peramivir in laboratory tests. Peramivir injection has recei
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 2015 PAREXEL International Corporation (NASDAQ: ... announced that Partnerships in Clinical Trials named PAREXEL,s ... Clinical Innovator of the Year.  The honor recognizes Mr. ... Company,s Perceptive MyTrials ® Data-Driven Monitoring solution. ... the 2015 Partnership Awards in Boston ...
(Date:4/23/2015)... 2015 The Thomas Brain Health ... a groundbreaking pilot study to see if early ... as little as three to six months. , ... nutritional medicine—will aggressively target and simultaneously treat the ... aging brain. These include oxidative stress, neuroinflammation, mitochondrial ...
(Date:4/23/2015)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... 2015 results before the Nasdaq market opens on Thursday, ... call and webcast to discuss its financial results and ... at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time). ... by dialing 866-952-1906 (US) or 785-424-1825 (International) using the ...
(Date:4/23/2015)... 2015  Veracyte, Inc. (NASDAQ: VCYT ) today ... to sell approximately $40 million of its common stock ... will purchase an aggregate of 4,907,975 shares of common ... the closing stock price on April 22, 2015. The ... including Broadfin Capital, Camber Capital, Deerfield, Longwood Capital Partners ...
Breaking Biology Technology:PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 3PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 5New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4
... Complete Genomics Inc.,a newly launched, third-generation human genome ... Annual BIO Investor Forum,which will be held in San ... president and chief executive officer of,Complete Genomics, will present ... Room of the Palace Hotel, located at 2 New ...
... Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced today that ... Conference on October 28, 2008 at 2:00 p.m.,Pacific Time ... in La,Jolla, California. Jack Lief, Arena,s President and Chief ... company, including its,clinical development and discovery programs., A ...
... demonstrated that low dose sublingual Intermezzo(R), used at ... significantly shortened time to ... Oct. 22 Transcept,Pharmaceuticals, Inc., a privately-held specialty pharmaceutical ... safety and efficacy of,its lead product candidate, Intermezzo(R) (zolpidem ...
Cached Biology Technology:Arena Pharmaceuticals to Present at the BIOCOM Investor Conference 2Arena Pharmaceuticals to Present at the BIOCOM Investor Conference 3Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP 2Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP 3Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP 4Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP 5Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP 6
(Date:3/19/2015)... Conn. , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, announces ... in a news clip that aired this week on ... ) . In a segment "The Next Great ... wallet ,a new way to pay, and ,a really big ...
(Date:3/17/2015)... MedNet Solutions , a global ... management systems, is pleased to announce that company ... in Clinical Trials Southeast conference – March 24-25 ... forum for MedNet to showcase iMedNet , ... eClinical technology platform. We strongly encourage ...
(Date:3/17/2015)... YORK , March 17, 2015  MecklerMedia ... the largest exhibition for service robots ever held ... RoboUniverse takes place on May 11-13, 2015 at ... and exhibitors for the event include: Acorn Product ... Control; EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic Corporation; ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... Purdue University researchers are collaborating with Chrysler LLC in ... from a contaminated site in north-central Indiana. The ... a former oil storage facility near Kokomo, Ind., this ... been shown to be capable of absorbing trichloroethylene, or ...
... -- Rice University bioengineer Jennifer West is being recognized ... scientific honors, the O,Donnell Award from The Academy of ... O,Donnell Awards, given for excellence in medical, scientific and ... an inscribed statue. West, a pioneer in the field ...
... Ala. A drug originally used to treat iron ... heal and re-grow injured bones, according to researchers at ... researchers injected the drug deferoxamine (DF), which is designed ... found DF triggered the growth of new blood vessels, ...
Cached Biology News:Fighting pollution the poplar way: Trees to clean up Indiana site 2Fighting pollution the poplar way: Trees to clean up Indiana site 3Rice's West honored as one of Texas' best researchers 2Rice's West honored as one of Texas' best researchers 3New treatment boosts bone healing and regrowth 2
... The Rapid-Screen cDNA Library Panels were designed ... three sets of PCRs to identify the ... is performed in a 96-well "Master Plate," ... 5,000 clones. Having identified the positive well(s) ...
... The Rapid-Screen cDNA Library Panels were designed ... three sets of PCRs to identify the ... is performed in a 96-well "Master Plate," ... 5,000 clones. Having identified the positive well(s) ...
... cDNA Library Panels were designed for full-length ... of PCRs to identify the desired cDNA ... in a 96-well "Master Plate," where each ... Having identified the positive well(s) by gel ...
... a modification of the procedure of ... 11 , 1055 (1969). ... an A 260 of 1.0 ... cm light path). Physical Form: lyophilized ...
Biology Products: